Mesoblast Share Price and Company Fundamentals

0.010 (0.500%)
52 week
1.7 - 5.7

Last traded: Today at 3:30 AM

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activitiesA biotechnology company in the area of adult stem cell technology.
Industry / SectorBiotechnology / Healthcare
Full time employees102
Mailing address55 Collins Street Level 38 Melbourne VIC 3000 Australia
Phone / Fax61 3 9639 6036 / 61 3 9639 6030


Mesoblast does not pay dividends.

Company Executives

As of Aug 2021, following are the company executives and directors listed on Mesoblast.

NameTitleAgeTotal Pay
Dr. Silviu ItescuFounder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director631.67M
Mr. Josh Muntner BFA, M.B.A.Chief Financial Officer51934.84k
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons)Gen. Counsel & Corp. Exec.52
Mr. Michael Schuster M.B.A., MS, BSc, MBAHead of Pharma Partnering43
Dr. Eric Strati M.B.A., Ph.D., Pharm.D., MBASr. VP of Commercial
Dr. Fred GrossmanChief Medical Officer
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S.Chief Operating Officer56
Sir Jonathan Richard Symonds CBE, BA, FCAHead of Corp. Fin. & Strategy61
Mr. Roger D. Brown BAHead of Spinal Orthopedic Disorders
Dr. Paul J. Simmons BSc, Ph.D.Head of Research & New Product Devel.61

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Mesoblast is 1.3B and its enterprise value is 1.41B. The enterprise value to revenue ratio of MSB is 228.29.

The MSB's stocks Beta value is 2.58 making it 158% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Mesoblast (MSB)

Mesoblast (ASX:MSB) Frequently Asked Questions

1. What is Mesoblast's Stock Symbol?

Mesoblast trades on ASX under the ticker symbol "MSB".

2. What is Mesoblast's stock price today?

One share of MSB stock can currently be purchased for approximately $2.01.

3. How can I contact Mesoblast?

Mesoblast's mailing address is 55 Collins Street Level 38 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9639 6036.

4. What is Mesoblast's official website?

The official website of Mesoblast is

5. Which share registry manages Mesoblast's stock?

Mesoblast's stock is managed by LINK MARKET SERVICES LIMITED.